We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cardiac Marker POC Tests Now Widely Used in Hospitals

By LabMedica International staff writers
Posted on 04 Jan 2010
Cardiac marker point-of-care (POC) tests are now widely used in hospitals and have emerged as a successful model of the concept of point-of-care diagnostics, according to a new market report.

The 2008 world market for POC cardiac enzymes and tests is estimated at US$490 million, and growing at 12% a year for the past three years, according to healthcare market research publisher Kalorama Information (New York, NY, USA). Cardiac markers are specific enzymes or proteins that tend to be concentrated when a cardiac event is likely to occur. Brain natriuretic peptide (BNP), CK-MB (creatine kinase, muscle and brain [subunits]), myoglobin, and troponin I/T are the most commonly tested markers. Testing for these markers can effectively indicate when intervention is or is not necessary. Lab-based tests can take up to 24 hours, which has driven demand for the point-of-care products that can deliver "stat” results.

"After many years of tests to prove effectiveness, there has been the stark realization that cardiac markers are useful to rule out or rule in the variety of cardiovascular conditions that are present in an ER [emergency room],” said Shara Rosen, the report's author.

The leaders in the cardiac enzyme POC market are Inverness's (Waltham, MA, USA) Triage, Siemens Healthcare's (Erlangen, Germany) Stratus, and Roche's (Nutley, NJ, USA) POC systems (Accutrend Plus, Roche Cardiac 200, Cobas h232). Of all POC testing that occurs in hospitals, cardiac marker tests are the fastest growing segment. Also at least another 20 companies market test strips for all or one of the marker panels. These companies' rapid tests help physicians triage cardiac patients more quickly.

Point-of-care or decentralized testing has long been the standard of care for glucose, but in other areas, results have been mixed. Products have been utilized, but never in the numbers that were predicted when the technologies were developed. The growth of cardiac markers is one part of a significant trend towards the use of POC tests, which now represent 15 percent of all tests conducted in hospitals.

POC testing has expanded because of studies that demonstrate the clinical effectiveness of these tests and technologic advancements that have increased their accuracy. Kalorama's research looked at the current state of glucose testing, as well as other emerging POC test categories, including the fast growing infectious disease and cholesterol test segments.

Kalorama Information supplies independent market research in the life sciences, as well as a full range of custom research services.

Related Links:

Kalorama Information




Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Automated Blood Typing System
IH-500 NEXT
New
Histamine ELISA
Histamine ELISA
New
Rocking Shaker
HumaRock

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests